By: Kairos Ventures On: December 6, 2019 In: MixComm, Portfolio News

Congratulations to the leadership team at MixComm, Inc. for recruiting Aristotele Hadjichristos as Vice President of Product Development.

Read more
By: Kairos Ventures On: November 19, 2019 In: 3D Bio, Portfolio News

3D Bio has received Orphan Drug Designation for AuriNovo™, an investigational combination product for reconstruction of the outer ear...

Read more
By: Kairos Ventures On: November 14, 2019 In: Portfolio News, Tanvas

Congratulations to our portfolio company Tanvas on being named a Cool Vendor in Gartner, Inc.'s report Cool Vendors...

Read more

Actuate Therapeutics, Inc. has raised an additional $6.5M in a Series B-3 financing round led by Bios Partners with...

Read more
By: Kairos Ventures On: November 12, 2019 In: Auspion, GuRu, Portfolio News

GuRu, a millimeter-wave (mmWave) technology company, has raised $15 million in Series A funding backed by Kairos Ventures and...

Read more
By: Kairos Ventures On: November 11, 2019 In: MixComm, Portfolio News

Congratulations to MixComm for securing $8.6M in Series B funding. Led by Kairos Ventures, these funds will be used...

Read more
By: Kairos Ventures On: October 23, 2019 In: Portfolio News, Provivi

Congratulations to Provivi for completing an $85 million Series C financing! Proceeds from the Series C financing will support...

Read more
By: Kairos Ventures On: October 14, 2019 In: Delpor, Portfolio News

The National Institutes of Health (NIH) has awarded Delpor, Inc. a grant for the development of a Once-Yearly Naltrexone...

Read more
By: Kairos Ventures On: September 25, 2019 In: Linnaeus, Portfolio News

Congratulations to Linnaeus for receiving clearance from the FDA for the company's investigational new drug application (IND) for LNS8801...

Read more
By: Kairos Ventures On: September 23, 2019 In: Linnaeus, Portfolio News

We are delighted to announce that Linnaeus Therapeutics, Inc. has closed a $12 million series B financing led by...

Read more